Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease

B TOKYO and CAMBRIDGE, Mass., May 8, 2026 /PRNewswire/ — Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and…
posteditor
posteditor
Articles: 21727

Other News